CytoReason Raises $80 Million to Expand AI Disease Models and Establish US Hub
CytoReason, a trailblazer in computational disease models for biopharma R&D, has secured $80 million in a funding round led by OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific. This substantial investment marks a pivotal moment for CytoReason as it accelerates its mission to revolutionize pharmaceutical decision-making through advanced AI technology. The new funding will propel CytoReason’s…